Product Code: MD 6656
The global negative pressure wound therapy market is projected to reach USD 3.84 billion by 2030 from USD 2.76 billion in 2025, at a CAGR of 6.9% during the forecast period.
Scope of the Report |
Years Considered for the Study | 2024-2030 |
Base Year | 2024 |
Forecast Period | 2024-2030 |
Units Considered | Value (USD billion) |
Segments | Product type, Wound type, and End User |
Regions covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
This is due to the increasing rise of diabetic patients, rising cases of traumatic injuries and burn injuries, and the growing geriatric population, which drives market growth. Additionally, rising usage of simplified single-use devices is expected to impact market growth.
"The hospitals segment of the negative pressure wound therapy market, by end user, is expected to hold the largest position during the forecast period."
Based on the end user, the negative pressure wound therapy market is divided into home care settings, hospitals, and other end users. Among these, hospitals hold the largest market share in 2024. The need for advanced wound care products in hospitals has been further stimulated by the rising incidence of diabetic foot ulcers and post-operative wounds. Hospital visits for wound care have also increased as a result of the growing geriatric population with chronic illnesses, including diabetes and vascular diseases. Hospitals can treat wounds quickly and effectively due to established protocols, knowledgeable medical staff, and a wide range of traditional wound care materials. As a result of the increased focus on improving wound care practices and patient recovery rates, this market segment continues to hold its dominant position.
"The burns and surgical & open wounds accounted for the largest market share in the negative pressure wound therapy market."
The negative pressure wound therapy market is segmented into burns and surgical & open wounds, pressure ulcers, diabetic foot ulcers, venous leg ulcers, and traumatic wounds. The burns and surgical & open wounds segment accounted for the largest share in the negative pressure wound therapy market in 2024. Burns and surgical & open wounds are leading segments in the negative pressure wound therapy market due to their rising occurrence and complexity, which require advanced wound management solutions. NPWT devices are particularly effective in managing these types of wounds, as they promote quicker healing, reduce infection risk, and improve tissue regeneration. Surgical wounds involving large incisions or at risk of dehiscence benefit significantly from maintaining a clean, moist wound environment and reducing edema.
"Asia Pacific is the fastest-growing region of the negative pressure wound therapy market by region."
The global negative pressure wound therapy market is segmented into five segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific negative pressure wound therapy market is growing due to the geriatric population, rising healthcare costs, and a growing incidence of chronic wounds. Asia Pacific offers high growth opportunities for players in the market. This segment is slated to register the highest CAGR during the forecast period.
As the number of surgeries, road accidents, and burn cases increases, there is an increasing need for effective wound care therapies. The growing incidence of diabetes has led to a rise in diabetic foot ulcers, highlighting the significance of proper wound care. The expansion of the healthcare system, e-commerce, and pharmacies has made the negative pressure wound therapy product accessible than ever. As awareness of wound care improves and healthcare services advance, the demand for negative pressure wound therapy solutions in the Mexico region is expected to see continued growth.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1: 38%, Tier 2: 29%, and Tier 3: 33%
- By Designation: C Level: 27%, Director Level: 18%, and Others: 55%
- By Region: North America: 50%, Europe: 20%, Asia Pacific: 20%, Latin America: 7%, and Middle East & Africa: 3%
Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.
Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the negative pressure wound therapy market are Solventum (US), Smith+Nephew (UK), Cardinal Health (US), Molnlycke AB (Sweden), Convatec Group PLC (UK), PAUL HARTMANN AG (Germany), Avery Dennison Corporation (US), BenQ Materials Corporation (Taiwan), Double Medical Technology Inc. (China), Advanced Oxygen Therapy Inc. (US), and Carilex Medical (Taiwan).
Research Coverage
This report studies the negative pressure wound therapy market based on product type, wound type, end user, and country. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.
This report provides insights on the following pointers:
- Analysis of key drivers (booming geriatric population, increasing cases of traumatic injuries, growing prevalence of chronic diseases
rising incidence of burn injuries
and favorable government and industry initiatives and reimbursements), restraints (high cost of negative pressure wound devices,
and risks associated with use of negative pressure wound therapy products), opportunities (high growth opportunities in emerging economies
and growing usage of simplified single-use devices), challenges (availability of alternative therapies, and Limited awareness among healthcare providers)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the negative pressure wound therapy market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the negative pressure wound therapy market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the negative pressure wound therapy market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Primary sources
- 2.1.2.2 Key industry insights
- 2.1.2.3 Key data from primary sources
- 2.1.2.4 Breakdown of primary interviews
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 BOTTOM-UP APPROACH
- 2.2.1.1 Approach 1: Company revenue estimation approach
- 2.2.1.2 Approach 2: Presentations of companies and primary interviews
- 2.2.1.3 Approach 3: Primary interviews
- 2.2.1.4 Growth forecast
- 2.2.1.5 CAGR projections
- 2.2.2 TOP-DOWN APPROACH
- 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.4 RESEARCH ASSUMPTIONS
- 2.4.1 STUDY-RELATED ASSUMPTIONS
- 2.4.2 PARAMETRIC ASSUMPTIONS
- 2.4.3 GROWTH RATE ASSUMPTIONS
- 2.5 RESEARCH LIMITATIONS
- 2.6 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 NEGATIVE PRESSURE WOUND THERAPY MARKET OVERVIEW
- 4.2 ASIA PACIFIC NEGATIVE PRESSURE WOUND THERAPY MARKET, BY END USER AND COUNTRY
- 4.3 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY KEY COUNTRY
- 4.4 NEGATIVE PRESSURE WOUND THERAPY MARKET, REGIONAL MIX, 2025 VS. 2030
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Booming geriatric population
- 5.2.1.2 Increasing cases of traumatic injuries
- 5.2.1.3 Growing prevalence of chronic diseases
- 5.2.1.4 Rising incidence of burn injuries
- 5.2.1.5 Favorable government and industry initiatives and reimbursement policies
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of negative pressure wound therapy devices
- 5.2.2.2 Risks associated with use of negative pressure wound therapy products
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Growth opportunities in emerging economies
- 5.2.3.2 Increasing use of simplified single-use devices
- 5.2.4 CHALLENGES
- 5.2.4.1 Availability of alternative therapies
- 5.2.4.2 Limited awareness among healthcare providers
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
- 5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
- 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 SUPPLY CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 INVESTMENT AND FUNDING SCENARIO
- 5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
- 5.9.1.1 Vacuum-assisted Closure (VAC) Therapy
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
- 5.9.2.1 Topical Oxygen Therapy
- 5.9.3 ADJACENT TECHNOLOGIES
- 5.9.3.1 Hyperbaric Oxygen Therapy
- 5.10 PATENT ANALYSIS
- 5.11 TRADE ANALYSIS
- 5.11.1 IMPORT DATA (HS CODE 901890)
- 5.11.2 EXPORT DATA (HS CODE 901890)
- 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
- 5.13 CASE STUDY ANALYSIS
- 5.13.1 CASE STUDY 1: COMPLEX WOUND HEALING WITH TOPICAL NEGATIVE PRESSURE WOUND THERAPY
- 5.13.2 CASE STUDY 2: NECROTIZING FASCIITIS MANAGED WITH NEGATIVE PRESSURE WOUND THERAPY FOR BETTER WOUND CLOSURE
- 5.13.3 CASE STUDY 3: TREATMENT OF HARD-TO-HEAL WOUNDS WITH PORTABLE NEGATIVE PRESSURE WOUND THERAPY
- 5.14 REGULATORY LANDSCAPE
- 5.14.1 REGULATORY ANALYSIS
- 5.14.1.1 North America
- 5.14.1.1.1 US
- 5.14.1.1.2 Canada
- 5.14.1.2 Europe
- 5.14.1.2.1 Germany
- 5.14.1.2.2 UK
- 5.14.1.2.3 France
- 5.14.1.3 Asia Pacific
- 5.14.1.3.1 China
- 5.14.1.3.2 Japan
- 5.14.1.3.3 India
- 5.14.1.4 Latin America
- 5.14.1.5 Middle East
- 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.14.2.1 North America
- 5.14.2.2 Europe
- 5.14.2.3 Asia Pacific
- 5.14.2.4 Latin America
- 5.14.2.5 Rest of the World
- 5.15 PORTER'S FIVE FORCES ANALYSIS
- 5.15.1 BARGAINING POWER OF SUPPLIERS
- 5.15.2 BARGAINING POWER OF BUYERS
- 5.15.3 THREAT OF NEW ENTRANTS
- 5.15.4 THREAT OF SUBSTITUTES
- 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.16.2 BUYING CRITERIA
- 5.17 IMPACT OF AI ON NEGATIVE PRESSURE WOUND THERAPY MARKET
- 5.17.1 INTRODUCTION
- 5.17.2 MARKET POTENTIAL OF AI IN NEGATIVE PRESSURE WOUND THERAPY MARKET
- 5.17.3 AI USE CASES
- 5.17.4 KEY COMPANIES IMPLEMENTING AI
- 5.17.5 FUTURE OF AI IN NEGATIVE PRESSURE WOUND THERAPY MARKET
- 5.18 IMPACT OF US TARIFF REGULATION ON NEGATIVE PRESSURE WOUND THERAPY MARKET
- 5.18.1 INTRODUCTION
- 5.18.2 KEY TARIFF RATES
- 5.18.3 PRICE IMPACT ANALYSIS
- 5.18.4 KEY IMPACT ON COUNTRY/REGION
- 5.18.4.1 North America
- 5.18.4.2 Europe
- 5.18.4.3 Asia Pacific
- 5.18.5 IMPACT ON END-USE INDUSTRIES
6 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY PRODUCT TYPE
- 6.1 INTRODUCTION
- 6.2 CONVENTIONAL NPWT DEVICES
- 6.2.1 RISING FOCUS ON EFFECTIVE WOUND MANAGEMENT TO EXPEDITE GROWTH
- 6.3 SINGLE-USE NPWT DEVICES
- 6.3.1 INCREASING ADOPTION OF SINGLE-USE DEVICES IN HOME HEALTHCARE TO PROMOTE GROWTH
- 6.4 NPWT ACCESSORIES & CONSUMABLES
- 6.4.1 GROWING PREVALENCE OF CHRONIC WOUNDS TO DRIVE MARKET
7 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY WOUND TYPE
- 7.1 INTRODUCTION
- 7.2 BURNS AND SURGICAL & OPEN WOUNDS
- 7.2.1 HIGH INCIDENCE OF BURN INJURIES IN LOW AND MIDDLE-INCOME COUNTRIES TO AID GROWTH
- 7.3 PRESSURE ULCERS
- 7.3.1 INCREASING AGING POPULATION WORLDWIDE TO AUGMENT GROWTH
- 7.4 DIABETIC FOOT ULCERS
- 7.4.1 INCREASE PREVALENCE OF DIABETES TO STIMULATE GROWTH
- 7.5 VENOUS LEG ULCERS
- 7.5.1 RISING PREVALENCE OF OBESITY TO CONTRIBUTE TO GROWTH
- 7.6 TRAUMATIC WOUNDS
- 7.6.1 GROWING INCIDENCE OF TRAUMATIC INJURIES TO BOOST MARKET
8 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY END USER
- 8.1 INTRODUCTION
- 8.2 HOSPITALS
- 8.2.1 RISING NUMBER OF SURGERIES TO ACCELERATE GROWTH
- 8.3 HOME CARE SETTINGS
- 8.3.1 INCREASING HEALTHCARE EXPENDITURE TO SPEED UP GROWTH
- 8.4 OTHER END USERS
9 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY REGION
- 9.1 INTRODUCTION
- 9.2 NORTH AMERICA
- 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 9.2.2 US
- 9.2.2.1 Rising regulatory approvals and favorable reimbursement policies to stimulate growth
- 9.2.3 CANADA
- 9.2.3.1 Increasing prevalence of diabetes to support growth
- 9.3 EUROPE
- 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 9.3.2 UK
- 9.3.2.1 Increase in research & development activities to aid growth
- 9.3.3 GERMANY
- 9.3.3.1 Growing prevalence of hospital-acquired infections to propel market
- 9.3.4 FRANCE
- 9.3.4.1 Rise in healthcare budget to spur growth
- 9.3.5 ITALY
- 9.3.5.1 Increasing national healthcare funding to favor growth
- 9.3.6 SPAIN
- 9.3.6.1 Increasing number of surgical procedures to promote growth
- 9.3.7 RUSSIA
- 9.3.7.1 Escalating diabetes issue to drive market
- 9.3.8 REST OF EUROPE
- 9.4 ASIA PACIFIC
- 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 9.4.2 CHINA
- 9.4.2.1 Increasing incidence of diabetic foot ulcers to encourage growth
- 9.4.3 JAPAN
- 9.4.3.1 Evolving healthcare delivery and infrastructure landscape to fuel market
- 9.4.4 INDIA
- 9.4.4.1 Booming medical tourism to speed up growth
- 9.4.5 AUSTRALIA
- 9.4.5.1 Growing focus on diabetes management to drive market
- 9.4.6 SOUTH KOREA
- 9.4.6.1 Increasing awareness and focus on advanced wound care therapies to facilitate growth
- 9.4.7 SINGAPORE
- 9.4.7.1 Increasing healthcare spending to sustain growth
- 9.4.8 REST OF ASIA PACIFIC
- 9.5 LATIN AMERICA
- 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 9.5.2 BRAZIL
- 9.5.2.1 Free healthcare services to bolster growth
- 9.5.3 MEXICO
- 9.5.3.1 Expanding hospital infrastructure to aid growth
- 9.5.4 REST OF LATIN AMERICA
- 9.6 MIDDLE EAST & AFRICA
- 9.6.1 GROWING DEMAND FOR HEALTHCARE FACILITIES TO DRIVE MARKET
- 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
- 10.1 OVERVIEW
- 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2024
- 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN NEGATIVE PRESSURE WOUND THERAPY MARKET
- 10.3 REVENUE ANALYSIS, 2022-2024
- 10.4 MARKET SHARE ANALYSIS, 2024
- 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 10.5.1 STARS
- 10.5.2 EMERGING LEADERS
- 10.5.3 PERVASIVE PLAYERS
- 10.5.4 PARTICIPANTS
- 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 10.5.5.1 Company footprint
- 10.5.5.2 Region footprint
- 10.5.5.3 Product type footprint
- 10.5.5.4 Wound type footprint
- 10.5.5.5 End-user footprint
- 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 10.6.1 PROGRESSIVE COMPANIES
- 10.6.2 RESPONSIVE COMPANIES
- 10.6.3 DYNAMIC COMPANIES
- 10.6.4 STARTING BLOCKS
- 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 10.6.5.1 Detailed list of key startups/SMEs
- 10.6.5.2 Competitive benchmarking of key startups/SMEs
- 10.7 COMPANY VALUATION AND FINANCIAL METRICS
- 10.7.1 COMPANY VALUATION
- 10.7.2 FINANCIAL METRICS
- 10.8 BRAND/PRODUCT COMPARISON
- 10.9 COMPETITIVE SCENARIO
- 10.9.1 PRODUCT LAUNCHES AND APPROVALS
- 10.9.2 DEALS
- 10.9.3 EXPANSIONS
- 10.9.4 OTHER DEVELOPMENTS
11 COMPANY PROFILES
- 11.1 KEY PLAYERS
- 11.1.1 SOLVENTUM
- 11.1.1.1 Business overview
- 11.1.1.2 Products offered
- 11.1.1.3 Recent developments
- 11.1.1.3.1 Product launches and approvals
- 11.1.1.3.2 Other developments
- 11.1.1.4 MnM view
- 11.1.1.4.1 Key strengths
- 11.1.1.4.2 Strategic choices
- 11.1.1.4.3 Weaknesses and competitive threats
- 11.1.2 SMITH+NEPHEW
- 11.1.2.1 Business overview
- 11.1.2.2 Products offered
- 11.1.2.3 Recent developments
- 11.1.2.3.1 Product launches and approvals
- 11.1.2.3.2 Deals
- 11.1.2.3.3 Expansions
- 11.1.2.4 MnM view
- 11.1.2.4.1 Key strengths
- 11.1.2.4.2 Strategic choices
- 11.1.2.4.3 Weaknesses and competitive threats
- 11.1.3 CARDINAL HEALTH
- 11.1.3.1 Business overview
- 11.1.3.2 Products offered
- 11.1.3.3 Recent developments
- 11.1.3.3.1 Deals
- 11.1.3.3.2 Expansions
- 11.1.3.4 MnM view
- 11.1.3.4.1 Key strengths
- 11.1.3.4.2 Strategic choices
- 11.1.3.4.3 Weaknesses and competitive threats
- 11.1.4 MOLNLYCKE AB
- 11.1.4.1 Business overview
- 11.1.4.2 Products offered
- 11.1.4.3 Recent developments
- 11.1.4.4 MnM view
- 11.1.4.4.1 Key strengths
- 11.1.4.4.2 Strategic choices
- 11.1.4.4.3 Weaknesses and competitive threats
- 11.1.5 CONVATEC GROUP PLC
- 11.1.5.1 Business overview
- 11.1.5.2 Products offered
- 11.1.5.3 Recent developments
- 11.1.5.4 MnM view
- 11.1.5.4.1 Key strengths
- 11.1.5.4.2 Strategic choices
- 11.1.5.4.3 Weaknesses and competitive threats
- 11.1.6 PAUL HARTMANN AG
- 11.1.6.1 Business overview
- 11.1.6.2 Products offered
- 11.1.6.3 Recent developments
- 11.1.7 AVERY DENNISON CORPORATION
- 11.1.7.1 Business overview
- 11.1.7.2 Products offered
- 11.1.7.3 Recent developments
- 11.1.7.3.1 Deals
- 11.1.7.3.2 Expansions
- 11.1.8 BENQ MATERIALS CORPORATION
- 11.1.8.1 Business overview
- 11.1.8.2 Products offered
- 11.1.8.3 Recent developments
- 11.1.8.3.1 Deals
- 11.1.8.3.2 Other developments
- 11.1.9 ADVANCED OXYGEN THERAPY INC.
- 11.1.9.1 Business overview
- 11.1.9.2 Products offered
- 11.1.9.3 Recent developments
- 11.1.9.3.1 Product launches and approvals
- 11.2 OTHER PLAYERS
- 11.2.1 DOUBLE MEDICAL TECHNOLOGY INC.
- 11.2.2 CARILEX MEDICAL
- 11.2.3 DEROYAL INDUSTRIES, INC.
- 11.2.4 LOHMANN & RAUSCHER GMBH & CO. KG
- 11.2.5 MEDAXIS LLC
- 11.2.6 GENADYNE BIOTECHNOLOGIES, INC.
- 11.2.7 DIRECT HEALTHCARE GROUP
- 11.2.8 ALLEVA MEDICAL
- 11.2.9 CORK MEDICAL, LLC
- 11.2.10 PENSAR MEDICAL
- 11.2.11 HAROMED
- 11.2.12 GUANGZHOU RAINHOME PHARM & TECH CO., LTD.
- 11.2.13 GUARD MEDICAL
- 11.2.14 DATT MEDIPRODUCTS PRIVATE LIMITED
- 11.2.15 KORAZON MEDICAL DEVICES PRIVATE LIMITED
- 11.2.16 TRIAGE MEDITECH PVT. LTD.
12 APPENDIX
- 12.1 DISCUSSION GUIDE
- 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 12.3 CUSTOMIZATION OPTIONS
- 12.4 RELATED REPORTS
- 12.5 AUTHOR DETAILS